Terminated PHASE2 INTERVENTIONAL NCT00211367

Treatment of Radiation Retinopathy With Open-Label Anecortave Acetate Sterile Suspension (15 mg)

Sponsor: Alcon Research

Updated 5 times since 2017 Last updated: Jun 20, 2007 Started: Apr 30, 2004 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

poor enrollment

Other terminated trials from Alcon Research

See all terminations from Alcon Research

Listed as NCT00211367, this PHASE2 trial focuses on Eye Injuries and remains terminated or withdrawn. Sponsored by Alcon Research, it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alcon Research
Manhattan Eye, Ear & Throat Hospital

Data source: Manhattan Eye, Ear & Throat Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States